NEW YORK (GenomeWeb News) — Ipsogen today said it has co-exclusively licensed a biomarker from Xenomics linked to acute myeloid leukemia in order to develop and sell tests for the disease.  
  
Ipsogen’s diagnostics, which will be designed to stratify and monitor AML patients, will be based on NPM1 mutations that will integrate Ipsogen’s quantitative and standardized technology, including its FusionQuant and ProfileQuant tools, according to a statement.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.